enVVeno Medical Q3 2026 net loss narrows to $4.4 million
NVNO•enVVeno Medical’s third-quarter 2026 net loss narrowed year over year to $4.4 million, while operating expenses fell 8% to $4.5 million. The company ended the quarter with $18.5 million in cash and investments, which it expects to fund operations into the fourth quarter of 2027.
1. Quarterly results and cash
enVVeno Medical reported a third-quarter 2026 net loss of $4.4 million, down year over year, and operating expenses of $4.5 million, down 8%. Quarter-end cash and investments totaled $18.5 million; the company expects that amount to fund operations into the fourth quarter of 2027. Quarterly cash burn was $3 million, with $4 million to $5 million expected in the first half of 2027 as TAVVE enrollment continues.
2. TAVVE study timeline
The FDA-approved TAVVE pivotal study remains on track to enroll its first patient before year-end 2026.
